An adult male underwent a bowel transplant for tufting enteropathy, receiving alemtuzumab, tacrolimus, and steroids immunosuppressants. Five years later, he developed an autoimmune hemolytic anemia, anti-IgG positive, with reduced reticulocyte count, leuckopenia and thrombocytopenia with antiplatelet antibodies. After an unsuccessful initial treatment with high dose steroids, reduction in tacrolimus dose, and intravenous immunoglobulin, a bone marrow biopsy revealed absence of erythroid maturation with precursor hyperplasia. The patient was switched to sirolimus and received four doses of rituximab plus two courses of plasmapheresis, which decreased his transfusion requirements. After a febrile episode one month later, the AIHA relapsed with corresponding decreases in platelet and leukocyte count: cyclosporine A was started with a second course of rituximab and IVIG without response, even though repeat bone marrow biopsy did not reveal morphology correlated to an acquired pure red cell aplasia. Considering the similarity in this clinical and laboratory findings to APRCA, alemtuzumab was added (three doses over a week) with CsA followed by steroids. The patient was eventually discherged transfusion-independent, with increasing hemoglobin levels and normal platelet and leukocyte count. One year later he is still disease-free with functioning graft.

Alemtuzumab plus cyclosporine treatment of the autoimmune hemolytic anemia in an adult bowel transplant

PASQUALINI, EDDI;M. Ravaioli;DI SIMONE, MASSIMO PIERLUIGI;PIRONI, LORIS;PINNA, ANTONIO DANIELE
2014

Abstract

An adult male underwent a bowel transplant for tufting enteropathy, receiving alemtuzumab, tacrolimus, and steroids immunosuppressants. Five years later, he developed an autoimmune hemolytic anemia, anti-IgG positive, with reduced reticulocyte count, leuckopenia and thrombocytopenia with antiplatelet antibodies. After an unsuccessful initial treatment with high dose steroids, reduction in tacrolimus dose, and intravenous immunoglobulin, a bone marrow biopsy revealed absence of erythroid maturation with precursor hyperplasia. The patient was switched to sirolimus and received four doses of rituximab plus two courses of plasmapheresis, which decreased his transfusion requirements. After a febrile episode one month later, the AIHA relapsed with corresponding decreases in platelet and leukocyte count: cyclosporine A was started with a second course of rituximab and IVIG without response, even though repeat bone marrow biopsy did not reveal morphology correlated to an acquired pure red cell aplasia. Considering the similarity in this clinical and laboratory findings to APRCA, alemtuzumab was added (three doses over a week) with CsA followed by steroids. The patient was eventually discherged transfusion-independent, with increasing hemoglobin levels and normal platelet and leukocyte count. One year later he is still disease-free with functioning graft.
A.Lauro; M.Stanzani; C.Finelli; C.Zanfi; M.C.Morelli; E.Pasqualini; A.Dazzi; M.Ravaioli; M.Di Simone; V.Giudice; L.Pironi; A.D.Pinna
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/412849
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact